$22.5M to smooth Fibrocell’s path to US launch of first cell-based wrinkle agent
This article was originally published in Scrip
Executive Summary
Fibrocell Science, which focuses on regenerative cell therapy for aesthetic and medical purposes, has raised $22.8 million in a private placement of stock and warrants.